AVX Pharma is a clinical-stage ophthalmology biotech company focused on developing novel therapies for Dry Eye Syndrome.
AVX Pharma is a clinical-stage ophthalmology biotech company focused on developing novel therapies for Dry Eye Syndrome.
Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface.
Lead product AVX-012, with a unique mechanism of action, is in Phase I/IIa clinical trials in Spain.